Premier Veterinary Group PLC Board Changes (2839W)
April 26 2016 - 2:01AM
UK Regulatory
TIDMPVG
RNS Number : 2839W
Premier Veterinary Group PLC
26 April 2016
PREMIER VETERINARY GROUP PLC
("PVG" or "the Company")
BOARD CHANGES
London, UK, 26 April 2016 - Premier Veterinary Group plc (LSE:
PVG) announces that Juliet Thompson has been appointed as a
director and as the independent non-executive Chairman of the
Company with effect from 25 April 2016. She succeeds as Chairman
Iain Ross who oversaw the successful reverse takeover of the
Company into Ark Therapeutics early last year. Iain Ross will
remain on the Board as a non-executive director.
Daniel Smith, the Chief Financial Officer, will be leaving the
Company in September this year to move to another part of the UK.
The Board has commenced a comprehensive recruitment process to
identify Daniel's replacement and a further announcement will be
made in due course.
Juliet Thompson, a chartered accountant, is currently also a
non-executive director of Nexstim, a medical technology company
quoted on Nasdaq in Finland and Sweden and was Vice President of
Corporate Finance of Precision Ocular, a company focused on retinal
diseases, for which she recently led a successful fundraising.
Juliet has built a strong track record advising healthcare
corporates on strategy and the capital markets. She formerly headed
up the healthcare team at Stifel and was a founder of Code
Securities, a healthcare investment banking boutique, which became
Nomura Code Securities where she was Head of Corporate Finance.
There are no further disclosures required under LR 9.6.13.
Iain Ross, non-executive and former Chairman commented:
"As previously indicated, we have been looking to strengthen our
Board with the appointment of an additional independent director.
Having been able to attract someone of Juliet's calibre, the Board
feels it is appropriate that she joins as our independent
non-executive Chairman. She brings extensive City and corporate
experience which will be invaluable as we seek to grow the business
aggressively."
For further information, please contact:
Premier Veterinary Group plc Tel: +44 (0)117 970 4130
Dominic Tonner, Chief Executive Officer
Daniel Smith, Chief Financial Officer
Square1 Consulting Tel: +44 (0)207 929 5599
David Bick/Brian Alexander
Note to Editors:
PVG's services to third party veterinary practices, through its
wholly-owned subsidiary Premier Vet Alliance ("PVA"), include the
administration and support of a preventative healthcare program for
pets branded "Pet Care Plan"; and the operation of a buying group
(the "PVA Buying Group") which offers enhanced discounts to member
practices on pharmaceutical and consumable spending.
Pet Care Plan is a structured, preventative healthcare program
for cats, dogs and rabbits and is available only through veterinary
practices. The program is seen as a way of providing gold standard
care for pets at an affordable price for the client, by way of
fixed monthly payments.
Pet Care Plan uses a clinical approach to prevention, as this is
the most effective method of ensuring illnesses are diagnosed more
quickly and not given a chance to advance. What truly sets Pet Care
Plan apart is its unique approach of offering an end-to-end
solution and support to the practice, which has been proven to work
extremely well. PVA works alongside practices to create a
tailor-made, cost-effective service for clients, one that delivers
excellent care to their patients and significantly improves
practice performance.
The PVA Buying Group, is now the UK's largest veterinary buying
group without group interests in veterinary practices or veterinary
wholesalers, offering its members the best discounts across the
industry on pharmaceutical and consumable spend.
For further details: http://www.premiervetalliance.co.uk/
This announcement includes "forward-looking statements" which
include all statements other than statements of historical facts,
including, without limitation, those regarding the Company's
financial position, business strategy, plans and objectives of
management for future operations, and any statements preceded by,
followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims",
"intends", "will", "can", "may", "anticipates", "would", "should",
"could" or similar expressions or the negative thereof. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors beyond the Company's
control that could cause the actual results, performance or
achievements of the Company to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements are
based on numerous assumptions regarding the Company's present and
future business strategies and the environment in which the Company
will operate in the future. These forward-looking statements speak
only as at the date of this announcement. The Company expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained in this
announcement to reflect any change in the Company's expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. As a result
of these factors, readers are cautioned not to rely on any
forward-looking statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUVOWRNWASUAR
(END) Dow Jones Newswires
April 26, 2016 02:01 ET (06:01 GMT)
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jul 2023 to Jul 2024